MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock from...
$259,384K
(457.61%↑ Y/Y)
Proceeds from issuance of
pre-funded warrants from...
$21,381K
(51.04%↑ Y/Y)
Proceeds from exercise of
stock options
$80K
(3900.00%↑ Y/Y)
Net cash provided by
financing activities
$241,752K
(245.24%↑ Y/Y)
Canceled cashflow
$39,093K
Net increase in
cash, cash...
-$16,784K
(-122.18%↓ Y/Y)
Canceled cashflow
$241,752K
Maturities of marketable
securities
$30,000K
(-50.00%↓ Y/Y)
Stock-based compensation
expense
$12,368K
(68.34%↑ Y/Y)
Accrued expenses and
other liabilities
$3,168K
(248.13%↑ Y/Y)
Non-cash lease expense
$423K
(-44.12%↓ Y/Y)
Depreciation expense
$260K
(-54.94%↓ Y/Y)
Other non-cash items
$19K
(-29.63%↓ Y/Y)
Repurchase of common stock,
including transaction...
$39,093K
Net cash provided by
(used in) investing...
-$226,035K
(-553.98%↓ Y/Y)
Canceled cashflow
$30,000K
Net cash used in
operating activities
-$32,501K
(26.35%↑ Y/Y)
Canceled cashflow
$16,238K
Purchases of marketable
securities
$256,014K
(2464.24%↑ Y/Y)
Purchases of property and
equipment
$21K
(-90.71%↓ Y/Y)
Net loss
-$45,637K
(16.27%↑ Y/Y)
Prepaid expenses and
other assets
$1,417K
(149.17%↑ Y/Y)
Other long-term
assets
$622K
(286.79%↑ Y/Y)
Operating lease
liabilities
-$397K
(39.57%↑ Y/Y)
Accretion income on
marketable securities
$340K
(-56.69%↓ Y/Y)
Accounts payable
-$326K
(67.98%↑ Y/Y)
Back
Back
Cash Flow
Aura Biosciences, Inc. (AURA)
Aura Biosciences, Inc. (AURA)
source: myfinsight.com